Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: A review

Roy O. Mathew, Sripal Bangalore, Michael P. Lavelle, Patricia Pellikka, Mandeep S. Sidhu, William E. Boden, Arif Asif

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Patients with chronic kidney disease (CKD) have a high prevalence of atherosclerotic cardiovascular disease, likely reflecting the presence of traditional risk factors. A greater distinguishing feature of atherosclerotic cardiovascular disease in CKD is the severity of the disease, which is reflective of an increase in inflammatory mediators and vascular calcification secondary to hyperparathyroidism of renal origin that are unique to patients with CKD. Additional components of atherosclerotic cardiovascular disease that are prominent in patients with CKD include microvascular disease and myocardial fibrosis. Therapeutic interventions that minimize cardiovascular events related to atherosclerotic cardiovascular disease in patients with CKD, as determined by well-designed clinical trials, are limited to statins. Data are lacking regarding other available therapeutic measures primarily due to exclusion of patients with CKD from major trials studying cardiovascular disease. Data from well-designed randomized controlled trials are needed to guide clinicians who care for this high-risk population in the management of atherosclerotic cardiovascular disease to improve clinical outcomes.

Original languageEnglish (US)
JournalKidney International
DOIs
StateAccepted/In press - Jul 19 2016

Fingerprint

Chronic Renal Insufficiency
Cardiovascular Diseases
Vascular Calcification
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Secondary Hyperparathyroidism
Cardiomyopathies
Fibrosis
Randomized Controlled Trials
Clinical Trials
Kidney
Therapeutics
Population

Keywords

  • Atherosclerotic cardiovascular disease
  • Chronic kidney disease
  • Diagnosis
  • Medical management
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease : A review. / Mathew, Roy O.; Bangalore, Sripal; Lavelle, Michael P.; Pellikka, Patricia; Sidhu, Mandeep S.; Boden, William E.; Asif, Arif.

In: Kidney International, 19.07.2016.

Research output: Contribution to journalArticle

Mathew, Roy O. ; Bangalore, Sripal ; Lavelle, Michael P. ; Pellikka, Patricia ; Sidhu, Mandeep S. ; Boden, William E. ; Asif, Arif. / Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease : A review. In: Kidney International. 2016.
@article{e8947d59443a46759780c8cede2057b0,
title = "Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: A review",
abstract = "Patients with chronic kidney disease (CKD) have a high prevalence of atherosclerotic cardiovascular disease, likely reflecting the presence of traditional risk factors. A greater distinguishing feature of atherosclerotic cardiovascular disease in CKD is the severity of the disease, which is reflective of an increase in inflammatory mediators and vascular calcification secondary to hyperparathyroidism of renal origin that are unique to patients with CKD. Additional components of atherosclerotic cardiovascular disease that are prominent in patients with CKD include microvascular disease and myocardial fibrosis. Therapeutic interventions that minimize cardiovascular events related to atherosclerotic cardiovascular disease in patients with CKD, as determined by well-designed clinical trials, are limited to statins. Data are lacking regarding other available therapeutic measures primarily due to exclusion of patients with CKD from major trials studying cardiovascular disease. Data from well-designed randomized controlled trials are needed to guide clinicians who care for this high-risk population in the management of atherosclerotic cardiovascular disease to improve clinical outcomes.",
keywords = "Atherosclerotic cardiovascular disease, Chronic kidney disease, Diagnosis, Medical management, Percutaneous coronary intervention",
author = "Mathew, {Roy O.} and Sripal Bangalore and Lavelle, {Michael P.} and Patricia Pellikka and Sidhu, {Mandeep S.} and Boden, {William E.} and Arif Asif",
year = "2016",
month = "7",
day = "19",
doi = "10.1016/j.kint.2016.09.049",
language = "English (US)",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease

T2 - A review

AU - Mathew, Roy O.

AU - Bangalore, Sripal

AU - Lavelle, Michael P.

AU - Pellikka, Patricia

AU - Sidhu, Mandeep S.

AU - Boden, William E.

AU - Asif, Arif

PY - 2016/7/19

Y1 - 2016/7/19

N2 - Patients with chronic kidney disease (CKD) have a high prevalence of atherosclerotic cardiovascular disease, likely reflecting the presence of traditional risk factors. A greater distinguishing feature of atherosclerotic cardiovascular disease in CKD is the severity of the disease, which is reflective of an increase in inflammatory mediators and vascular calcification secondary to hyperparathyroidism of renal origin that are unique to patients with CKD. Additional components of atherosclerotic cardiovascular disease that are prominent in patients with CKD include microvascular disease and myocardial fibrosis. Therapeutic interventions that minimize cardiovascular events related to atherosclerotic cardiovascular disease in patients with CKD, as determined by well-designed clinical trials, are limited to statins. Data are lacking regarding other available therapeutic measures primarily due to exclusion of patients with CKD from major trials studying cardiovascular disease. Data from well-designed randomized controlled trials are needed to guide clinicians who care for this high-risk population in the management of atherosclerotic cardiovascular disease to improve clinical outcomes.

AB - Patients with chronic kidney disease (CKD) have a high prevalence of atherosclerotic cardiovascular disease, likely reflecting the presence of traditional risk factors. A greater distinguishing feature of atherosclerotic cardiovascular disease in CKD is the severity of the disease, which is reflective of an increase in inflammatory mediators and vascular calcification secondary to hyperparathyroidism of renal origin that are unique to patients with CKD. Additional components of atherosclerotic cardiovascular disease that are prominent in patients with CKD include microvascular disease and myocardial fibrosis. Therapeutic interventions that minimize cardiovascular events related to atherosclerotic cardiovascular disease in patients with CKD, as determined by well-designed clinical trials, are limited to statins. Data are lacking regarding other available therapeutic measures primarily due to exclusion of patients with CKD from major trials studying cardiovascular disease. Data from well-designed randomized controlled trials are needed to guide clinicians who care for this high-risk population in the management of atherosclerotic cardiovascular disease to improve clinical outcomes.

KW - Atherosclerotic cardiovascular disease

KW - Chronic kidney disease

KW - Diagnosis

KW - Medical management

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=85009285154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009285154&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2016.09.049

DO - 10.1016/j.kint.2016.09.049

M3 - Article

C2 - 28040264

AN - SCOPUS:85009285154

JO - Kidney International

JF - Kidney International

SN - 0085-2538

ER -